Meeting
2017 ASCO Annual Meeting
KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.
Authors
Natasha B. Leighl
Princess Margaret Cancer Centre, Toronto, ON, Canada
Natasha B. Leighl , Matthew David Hellmann , Rina Hui , Enric Carcereny Costa , Myung-Ju Ahn , Joseph Paul Eder , Ani Sarkis Balmanoukian , Charu Aggarwal , Leora Horn , Amita Patnaik , Matthew A. Gubens , Suresh S. Ramalingam , Gregory M. Lubiniecki , Jin Zhang , Bilal Piperdi , Edward B. Garon , Enriqueta Felip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01295827
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9011)
DOI
10.1200/JCO.2017.35.15_suppl.9011
Abstract #
9011
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
First Author: Deborah Blythe Doroshow
Poster
2021 ASCO Annual Meeting
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.
First Author: Hiroshi Takumida
Poster
2020 ASCO Virtual Scientific Program
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
First Author: Joao Victor Machado Alessi